The Diacylglycerol O Acyltransferase pipeline drugs market research report outlays comprehensive information on the Diacylglycerol O Acyltransferase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Diacylglycerol O Acyltransferase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Metabolic Disorders, Dermatology, and Infectious Disease which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Dyslipidemia, Obesity, Acne Vulgaris, and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in Diacylglycerol O Acyltransferase targeted therapeutics development with respective active and dormant or discontinued products.
The Diacylglycerol O Acyltransferase pipeline targets constitutes close to 11 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 4, 2, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Diacylglycerol O Acyltransferase overview
Diacylglycerol O-acyltransferase 1 (DGAT1) is a multipass transmembrane protein that functions as a key metabolic enzyme. This protein catalyzes the conversion of diacylglycerol and fatty acyl CoA to triacylglycerol. This enzyme can also transfer acyl CoA to retinol. Activity of this protein may be associated with obesity and other metabolic diseases.
For a complete picture of Diacylglycerol O Acyltransferase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
